Only two compounds (Lilly's receptor antagonist and Isis' above mentioned receptor antisense oligodeoxyribonucleotide) are active in clinical testing despite the long-standing knowledge of the potential benefits of glucagon inhibition in diabetes and broad efforts to identify potent glucagon receptor antagonists. The gene discussed is GCGR; the disease is diabetes mellitus.